Project Grant R21AI187937
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $240K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $779,915 Project Grant to the Scripps Research Institute to investigate the chromatin remodeling functions of polyphosphate condensates in the bacterial pathogen Pseudomonas aeruginosa. The grant, awarded under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will support research to understand how polyphosphate, a polymer produced by bacteria in response to stress, interacts with the...
- This Project Grant, valued at $868,776.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to identify the direct regulatory targets of this regulator, called PhAF, under standard laboratory conditions and in clinically relevant...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $585,539 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the University of Illinois in Chicago. The grant supports research to understand how the pathogen Acinetobacter baumannii, a major public health threat due to its drug resistance, colonizes and persists in the human gut microbiome. The project aims to investigate A....
- This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Fimbrion Therapeutics Inc. to develop small molecule glycoside inhibitors targeting the LecB lectin protein in Pseudomonas aeruginosa (PA) bacteria. The goal is to create novel therapeutics to disrupt PA biofilm formation and enhance the efficacy of antibiotics in treating PA infections,...
- This $430,760 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which administers the Allergy and Infectious Diseases Research program (CFDA 93.855), to the University of Pittsburgh. The grant supports research to train neutrophils, a type of white blood cell, to defend against a lethal bacterial infection of the lung caused by Pseudomonas aeruginosa. The key objectives are to establish a strategy to improve the host's immune defense against this...
- This $540,818 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Columbia University on the interdependency of chemical, structural, and physiological heterogeneity in Pseudomonas aeruginosa biofilms. The project aims to investigate how biofilm and infection-site conditions impact P. aeruginosa's use of lactate as a carbon source, and how the bacteria tolerate...
- This Project Grant award, valued at $160,040.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research conducted by the University of California, San Francisco (UCSF) to investigate how the bacterial pathogen Pseudomonas aeruginosa senses and responds to mechanical deformation of its cell envelope when contacting surfaces. The research aims to further...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $439,896 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to William Marsh Rice University in Houston, Texas. The grant supports research to develop R pyocins, which are phage tail-like protein complexes, as a novel approach to target multidrug-resistant Pseudomonas aeruginosa, a serious bacterial threat. The research aims to leverage the strain-specific killing ability of R...
- This $158,000 Project Grant was awarded on June 9, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to investigate mechanisms of nitric oxide (NO) detoxification and reactivity in the bacterial pathogen Pseudomonas aeruginosa. The research aims to understand how this opportunistic pathogen persists during immune responses involving NO production, in order...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research on Pseudomonas aeruginosa infections and neutrophil swarming behavior. The funding will support a 2-year project to develop an ex vivo model to study how neutrophils coordinate to surround and neutralize large bacterial...